Want to see RANI full AI Analyst Report?
RANI Stock Chart & Stats
$0.96
-$0.04(-3.15%)
At close: 4:00 PM EST
$0.96
-$0.04(-3.15%)
Day’s Range― - ―
52-Week Range$0.39 - $3.87
Previous CloseN/A
Volume228.85K
Average Volume (3M)751.04K
Market Cap
$93.71M
Enterprise Value$44.28M
Total Cash (Recent Filing)$43.40M
Total Debt (Recent Filing)$3.94M
Price to Earnings (P/E)―
Beta2.58
Next Earnings
Aug 06, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding112,389,150
10 Day Avg. Volume632,982
30 Day Avg. Volume751,041
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.70
Price to Sales (P/S)54.68
P/FCF Ratio-4.75
Enterprise Value/Market Cap0.47
Enterprise Value/Revenue13.97
Enterprise Value/Gross Profit14.72
Enterprise Value/Ebitda-1.33
Forecast
1Y Price Target
$7.50Price Target Upside681.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.19
Revenue Forecast (FY)$2.42M
Bulls Say, Bears Say
Bulls Say
Proprietary Oral Biologic Delivery PlatformRani’s ingestible pill platform targets a durable competitive niche: oral delivery of biologics is technically complex and could displace injectables across multiple indications. This creates high technical barriers to entry and long-term licensing/partnership optionality if clinical and regulatory milestones validate the approach.
Strategic Collaborations And Pipeline ProgressActive partnerships (ProGen, Chugai) and an advancing RT-114 Phase 1 program materially de-risk development versus standalone discovery. Collaborations can provide non-dilutive milestone funding, regulatory and commercial expertise, and validation of the platform that sustains long-term business development and licensing prospects.
Improved Liquidity And Manageable LeverageReported cash balances plus a May equity financing and low debt-to-equity provide a multi-quarter runway into late 2027 per management. Manageable leverage improves funding optionality and reduces near-term solvency risk, allowing the company to advance clinical programs and partnership milestones without immediate operational distress.
Bears Say
Small, Declining Revenue BaseRevenue remains trivial relative to operating scale, reflecting limited commercialization traction. A persistently small and shrinking revenue base undermines internal funding capacity, makes fixed-cost absorption harder, and delays any pathway to self-sustaining operations absent material partnership or product commercialization events.
High Ongoing Cash Burn And Weak Cash GenerationSubstantial negative operating and free cash flow shows the business consumes significant capital to fund R&D and operations. Continued cash burn increases dependency on external financing, heightens dilution risk, and limits the firm’s ability to invest organically or scale unless milestones trigger partner payments or capital raises.
Nasdaq Bid-price Noncompliance And Listing RiskA formal Nasdaq noncompliance notice is a structural governance and capital-access risk: potential delisting or reverse split outcomes can complicate future financings, reduce investor appetite, and force management to prioritize short-term cure actions over long-term R&D planning until compliance is restored.
Rani Therapeutics Holdings News
RANI FAQ
What was Rani Therapeutics Holdings, Inc. Class A’s price range in the past 12 months?
Rani Therapeutics Holdings, Inc. Class A lowest stock price was $0.39 and its highest was $3.87 in the past 12 months.
What is Rani Therapeutics Holdings, Inc. Class A’s market cap?
Rani Therapeutics Holdings, Inc. Class A’s market cap is $93.71M.
When is Rani Therapeutics Holdings, Inc. Class A’s upcoming earnings report date?
Rani Therapeutics Holdings, Inc. Class A’s upcoming earnings report date is Aug 06, 2026 which is in 25 days.
How were Rani Therapeutics Holdings, Inc. Class A’s earnings last quarter?
Rani Therapeutics Holdings, Inc. Class A released its earnings results on May 15, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.045 by $0.005.
Is Rani Therapeutics Holdings, Inc. Class A overvalued?
According to Wall Street analysts Rani Therapeutics Holdings, Inc. Class A’s price is currently Undervalued.
Does Rani Therapeutics Holdings, Inc. Class A pay dividends?
Rani Therapeutics Holdings, Inc. Class A does not currently pay dividends.
What is Rani Therapeutics Holdings, Inc. Class A’s EPS estimate?
Rani Therapeutics Holdings, Inc. Class A’s EPS estimate is -0.05.
How many shares outstanding does Rani Therapeutics Holdings, Inc. Class A have?
Rani Therapeutics Holdings, Inc. Class A has 112,389,150 shares outstanding.
What happened to Rani Therapeutics Holdings, Inc. Class A’s price movement after its last earnings report?
Rani Therapeutics Holdings, Inc. Class A reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.045. Following the earnings report the stock price went down -10%.
Which hedge fund is a major shareholder of Rani Therapeutics Holdings, Inc. Class A?
Currently, no hedge funds are holding shares in RANI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rani Therapeutics Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.50 (681.25% Upside)
$7.50 (681.25% Upside)
Blogger Sentiment
Bullish
RANI Sentiment 70%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.8%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
4.09%
12-Months-Change
Fundamentals
Return on Equity
-245.45%
Trailing 12-Months
Asset Growth
115.04%
Trailing 12-Months
Company Description
Rani Therapeutics Holdings, Inc. Class A
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
RANI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant advancements in Rani's technology and pipeline, particularly in the obesity treatment market, supported by strategic partnerships and successful preclinical data. However, financial challenges remain, as evidenced by decreased cash reserves and a substantial net loss for the year.View all RANI earnings summariesRANI Stock 12 Month Forecast
Average Price Target
$7.50
▲(681.25% Upside)
Technical Analysis
Ownership Overview
24.70% Insiders
4.85% Mutual Funds
30.03% Other Institutional Investors
36.24% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---